Nadia Rosenthal holds a Chair in Cardiovascular Science at Imperial College London, where she started in 2005 as Scientific Director of the Magdi Yacoub Institute, and Head of the Heart Science Centre/Section within NHLI. She now directs a research laboratory in the new Imperial Centre for Translational and Experimental Medicine. She is also Founding Director of the Australian Regenerative Medicine Institute at Monash University in Melbourne, Australia (since 2007), Scientific Head of EMBL Australia (since 2009) and holds an NH&MRC Australia Fellowship (since 2010).
Born in the US, Professor Rosenthal obtained her PhD in 1981 from Harvard Medical School and trained as a postdoctoral fellow at NIH, then directed a biomedical research laboratory at Harvard Medical School, and served for a decade at the New England Journal of Medicine as editor of the Molecular Medicine series. From 2001-2012 she was Senior Scientist and Head of the Mouse Biology Unit at European Molecular Laboratory [EMBL] in Rome, Italy. She is an EMBO member, with numerous awards and honors including the Ferrari-Soave Prize in Cell Biology and a Doctors Honoris Causa from the Pierre and Marie Curie University in Paris and the University of Amsterdam. She participates on numerous Advisory Boards and Committees including the Scientific Advisory Boards of Keystone Symposia and the Centre for Molecular Medicine in Vienna. Professor Rosenthal is a Founding Editor of Disease Models and Mechanisms (2007) and Editor-in-Chief of Differentiation (2012). Her research uses mammalian genetics to explore the embryonic development of heart and skeletal muscle and the regeneration of adult tissues.
Professor Rosenthal’s research focuses on muscle and cardiac developmental genetics and the role of growth factors, stem cells and the immune system in tissue regeneration. Her work the biology of insulin-like growth factors has led to significant advances in novel cell-based therapies for muscle ageing and heart disease. She is a global leader in the use of targeted mutagenesis in mice to investigate muscle development, disease, and repair, and is a participant in EUCOMM, the European Conditional Mouse Mutagenesis Program, where she coordinates the selection and production of new Cre driver strains for the international mouse genetics community.
et al., 2024, Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002 (hydrogen sulfide donor), dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not significantly affect lifespan in either sex at the doses and schedules used., Geroscience, Vol:46, Pages:795-816
et al., 2023, Genetically diverse mouse models of SARS-CoV-2 infection reproduce clinical variation in type I interferon and cytokine responses in COVID-19, Nature Communications, Vol:14
et al., 2023, Genetic architecture of heart mitochondrial proteome influencing cardiac hypertrophy., Elife, Vol:12
et al., 2023, Canagliflozin retards age-related lesions in heart, kidney, liver, and adrenal gland in genetically heterogenous male mice, Geroscience, Vol:45, ISSN:2509-2715, Pages:385-397
et al., 2022, Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice., Aging Cell, Vol:21